Top in hem/onc: Phase 3 data on lung cancer therapy, new leadership at Mayo Clinic

Sumary of Top in hem/onc: Phase 3 data on lung cancer therapy, new leadership at Mayo Clinic:

  • Results of the GEMSTONE-301 study showed that sugemalimab was well tolerated and effective in patients with stage III non-small cell lung cancer..
  • Adobe Stock A randomized phase 3 study designed to evaluate sugemalimab (EQRx) as a treatment for stage III non-small cell lung cancer met its primary endpoint, according to a press release..
  • For a minority patients and other historically underrepresented populations, the COVID-19 pandemic has accentuated longstanding disparities in health care..
  • Aplin, PhD, has been appointed deputy director for scientific strategy at Sidney Kimmel Cancer Center — Jefferson Health….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close